Core--Cell therapy resource

细胞治疗中心的主要功能是通过提供关键设备和技术专长来协助项目2-6，这些设备和技术专长涵盖了三个不同的研究支持方面：犬和人类细胞的最佳冷冻保存和储存；犬移植产物的流式细胞术表征以及犬类器官的干细胞富集。具体而言，该中心将：(A)储存从暴露于不同剂量辐照下的狗和人身上获得的外周血和/或血清标本，作为生物剂量学开发项目2和3的一部分，并创建一个犬脐带血库，以支持项目5。(B)犬CD34+细胞富集，作为体外扩增髓细胞的起始材料

The primary functions of Cell Therapy Core are to assist Projects 2-6 by making available critical equipment and technical expertise covering three distinct aspects of research support: optimal cryopreservation and storage of canine and human cells; characterization of canine transplantation products by flow cytometry; and stem cell enrichment from canine components. Specifically, this Core will: (A) store peripheral blood and/or serum specimens obtained from dogs and humans exposed to varying doses of irradiation as part of biodosimetry development Projects 2 and 3, and create a canine cord blood bank in support of Project 5. (B) Enrich for canine CD34+ cells to be used as the starting material for the ex vivo expanded myeloid progenitor cell studies described in Projects 4 and 5. As part of these projects the development of more optimized cryopreservation and storage conditions for these types of cells will also be necessary. (C) Analyze by flow cytometry all the various canine components used for transplantation as part of Projects 4-6. This proposed Cell Therapy Core represents an enhancement of an already existing Cell Processing resource that has considerable expertise in each of these areas. The existing resource manages several Research and Clinical Cell Repositories that contain a variety of cell types, encompassing over 50,000 different specimens stored in the vapor phase of liquid nitrogen freezers, including components used to support human therapeutic studies. The Processing Core has performed over 30 canine CD34+ cell enrichments, achieving excellent purities of >80% and yields of 50%. Finally, the Core specializes in flow cytometry analysis, and has established a database with over 3500 human clinical transplant components characterized for the content of hematopoietic stem cells (CD34), T-cell subsets (CDS, CD4, CDS, CD45RA), dendritic cells (CD14, BDCA-2), B-cells (CD19, CD22) and NK cell (CD56) subsets. These data form the basis for important correlative studies to investigate associations of these cell types with several clinical outcomes. In summary, Cell Therapy Core D will provide unique and critical services in support of Projects 2-6 described in this grant application, specifically optimal cryopreservation and storage, cell selection, and flow cytometry analysis, and will be able to provide those services in a more efficient and cost-effective manner.